Based on evidence that cannabinoids and opioids can work in synergy to moderate pain, Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) and its research arm, Cannevert Therapeutics Ltd., intend to boost actions of opioid analgesics with a specific strain of cannabis. A recent article highlights the company’s approach in developing quality strains, stating, “Veritas Pharma employs a scientific approach to support medical cannabis claims and is intent on developing and commercializing the most effective strains of cannabis for medical use. The company is concerned that, with the rapid growth of the medical cannabis industry, product quality is inconsistent and scientific proof of effectiveness is lacking. By forming strategic alliances and partnerships within the industry, the company intends to address this issue. Its approach to research and development is aimed firstly at chemically profiling the various cultivars of cannabis. As a second step, each cultivar is pharmacologically profiled to identify strains for specific diseases before clinical trials are undertaken to establish each cultivar’s utility and efficacy. By using this approach, Veritas will provide physicians and patients the scientific evidence necessary to enable them to use its products with confidence.”
To view the full article, visit http://dtn.fm/G0BLt
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment